<DOC>
	<DOCNO>NCT01685021</DOCNO>
	<brief_summary>This open-label , multicentre study characterize safety preliminary efficacy human anti CD19 antibody MOR00208 adult subject relapsed/refractory B-cell acute lymphoblastic leukemia ( B-ALL )</brief_summary>
	<brief_title>Study Fc-Optimized Anti-CD19 Antibody ( MOR00208 ) Treat B-cell Acute Lymphoblastic Leukemia ( B-ALL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Patients previously treat Philadelphiachromosomenegative BALL , progression least one prior therapy . Patients Philadelphiachromosomepositive BALL include refractory intolerant least one tyrosinekinaseinhibitor . Male female patient least 16 year age ; patient le 18 year age , patient must ability understand give write assent addition parent's/guardian 's write informed consent . Patients histologically confirm diagnosis BALL Mixed phenotype acute leukemia patient B cell immunophenotype . Patients Eastern Cooperative Oncology Group performance status less equal 2 Patients total bilirubin less equal 2.0 mg/dL Patients alanine aminotransferase aspartate aminotransferase less equal 2.5 time upper limit normal Patients creatinine level less equal 2.0 mg/dL If female childbearing potential , confirmation negative pregnancy test enrollment use doublebarrier contraception , confirmation negative pregnancy test enrollment use oral contraceptive plus barrier contraceptive , confirmation undergone clinically document total hysterectomy , oophorectomy , tubal ligation If male , use effective barrier method contraception study 3 month last dose sexually active female childbearing potential Patients ability understand give write informed consent comply study protocol Patients receive previous treatment antiCD19 antibody fragment Receipt antiCD20 therapy great 4 week first study dose Patients undergone prior allogeneic stem cell transplantation within 3 month active graft versus host disease Patients know hypersensitivity excipient contain drug formulation Patients New York Heart Association Class III IV History stroke myocardial infarction within last 6 month Patients history positive human immunodeficiency virus test result ( ELISA western blot ) Patients positive hepatitis serology . Hepatitis B ( HBV ) : Patients positive serology hepatitis B , define positive hepatitis B surface antigen ( HbsAg ) total antihepatitis B core antibody ( antiHbc ) . Patients positive anti Hbc may include hepatitis B viral DNA detectable . Hepatitis C ( HCV ) : Patients positive hepatitis C serology ( define positive antihepatitis C virus antibody ( antiHCV ) unless HCVRNA confirm negative . Patients active viral , bacterial , systemic fungal infection require active parenteral treatment Patients receive active treatment/chemotherapy another primary malignancy receive treatment , include surgery , radiation , chemotherapy , within past 5 year ( except ductal breast cancer situ , nonmelanoma skin cancer , prostate cancer require treatment , cervical carcinoma situ ) Patients pregnant breastfeed Patients major surgery radiation therapy within 4 week prior first study dose</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>B-ALL</keyword>
	<keyword>CD19</keyword>
	<keyword>MOR208</keyword>
	<keyword>MOR00208</keyword>
	<keyword>Xmab5574</keyword>
	<keyword>B-cell acute lymphoblastic leukemia</keyword>
	<keyword>Fc-optimized Anti-CD19 Antibody</keyword>
</DOC>